The $32 billion multi-strategy alternative investment firm Investcorp announced the launch of a new platform dedicated to investment in Chinese healthcare companies.
The new platform advances the firm’s Asia growth strategy, officials said in a press release. The aim is to create a "curated" portfolio of primary and secondary stakes in ‘sector leading’ Chinese healthcare companies that have remained resilient through the pandemic and are expected to experience accelerated growth in the post-pandemic world.
So far Investcorp has already acquired minority equity stakes in Lu Daopei Medical Group and WeDoctor. The terms . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.
